Streetbeat News

Regulatory

ETHUSD

GBTC

Bernstein research suggests that the SEC's approval of spot Ethereum ETFs was not politically influenced, despite President Biden's recent veto of a bill aimed at overturning SAB 121. Analysts argue the decision was pragmatic to avoid legal conflicts, especially after Grayscale's legal victory over the SEC.

Portfolio Pulse from Murtuza Merchant

June 03, 2024 | 5:09 pm

DJIA

NDAQ

QQQ

SPY

NYSE equities are currently evaluating erroneous Limit-Up-Limit-Down (LULD) halts, which could impact trading and market stability.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 5:05 pm

BK

C

GS

JPM

KBE

KBWB

TFC

USB

WFC

Large bank stocks, including Goldman Sachs, JPMorgan, and Wells Fargo, have surged due to optimism for an economic 'soft landing.' The Invesco KBW Bank ETF and SPDR S&P Bank ETF have also seen significant gains. Bank of America has issued a positive outlook for the banking sector, highlighting the potential impact of the 2024 U.S. Election and changes in Basel III regulations. Despite recent declines in stock prices, BofA maintains Buy ratings for several major financial institutions.

Portfolio Pulse from Hayden Buckfire

June 03, 2024 | 4:18 pm

EIS

SPY

USO

The White House announced that if Hamas accepts the Gaza proposal and Phase One begins, the first batch of hostages would be released, and Israel would withdraw its military from population centers.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:14 pm

AGIO

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) shares surged after the Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary and secondary endpoints, showing significant reduction in transfusion burden compared to placebo. The company plans to submit a U.S. marketing application for Pyrukynd (mitapivat) by the end of 2024.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:11 pm

CRNX

Crinetics Pharmaceuticals presented new data from its Phase 3 PATHFNDR-2 trial at ENDO 2024, showing promising results for its oral, once-daily treatment for acromegaly, paltusotine. The data indicate rapid and sustained IGF-1 responses and fewer symptom exacerbations compared to standard care. Crinetics plans to complete the NDA submission for paltusotine in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:02 pm

GOOG

GOOGL

VGK

Google announced that starting in June 2024, its Google Ads Healthcare & Medicines Policy will be updated to allow online pharmacies to promote their services in Estonia and Lithuania.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:56 pm

LGMK

LogicMark has received a Notice of Allowance for its US patent application titled 'Environment Sensing For Care Systems'. This development could enhance the company's product offerings in the care systems market.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:56 pm

SPY

President Biden is expected to sign an executive order that bans migrants who cross the border illegally from claiming asylum, allowing for their quick deportation back to Mexico or their home countries.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:53 pm

CDXC

ChromaDex has received Orphan Drug Designation from the FDA for its Nicotinamide Riboside Chloride for the treatment of Ataxia Telangiectasia.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:51 pm